Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024

Rhea-AI Summary

Emergent BioSolutions Inc. (NYSE: EBS) has announced it will host a conference call on August 6, 2024, at 5:00 pm eastern time to discuss its second quarter 2024 financial results. The call will cover key business updates, revenue guidance for the third quarter of 2024, and full year guidance. Participants can join via webcast or telephone, with pre-registration required for phone access. A replay will be available on the company's Investors page. This announcement suggests that Emergent BioSolutions is preparing to provide important financial information and future projections, which could potentially impact investor sentiment and stock performance.

Positive

• Providing forward-looking guidance for Q3 2024 and full year
• Offering multiple access options for the earnings call, enhancing investor accessibility

Negative

• None.

GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial results for the second quarter 2024, key business updates, revenue guidance for the third quarter of 2024, as well as full year guidance.

Conference Call Information
Participants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com  

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

When will Emergent BioSolutions (EBS) release its Q2 2024 financial results?

Emergent BioSolutions (EBS) will release its Q2 2024 financial results on August 6, 2024, during a conference call at 5:00 pm eastern time.

What topics will be covered in Emergent BioSolutions' (EBS) Q2 2024 earnings call?

The earnings call will cover Q2 2024 financial results, key business updates, revenue guidance for Q3 2024, and full year guidance.

How can investors participate in Emergent BioSolutions' (EBS) Q2 2024 earnings call?

Investors can participate via webcast or telephone. Telephone participants must register in advance to receive dial-in information and access credentials.

Will there be a replay available for Emergent BioSolutions' (EBS) Q2 2024 earnings call?

Yes, a replay of the call will be accessible from the Investors page of Emergent BioSolutions' website.